Pfizer Q3 tests obesity pipeline against COVID decline
Alpha Vantage · 24/7 Wall St. · · AI-summarised by FinFlash
Pfizer reports third-quarter results on November 3, with investors weighing whether non-COVID growth can offset falling Paxlovid and Comirnaty sales. Launched and acquired products grew 18% last quarter, and obesity candidate berobenatide showed promising weight loss results. Pfizer targets a first obesity approval in 2028 and $9.7 billion in net savings by 2029.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.